SWOG 9343--ANDROGEN SUPPRESSION & FIXED SCHEDULE SURAMINE IN PROSTATE CA

在本研究中，主要目标是评估FIXED的可行性 计划苏拉明联合雄激素抑制(切除加 氟他胺，或LHRH激动剂加氟他胺)在合作小组环境中 在新诊断的D2期前列腺癌患者中。可行性 评估的基础是评估与苏拉明有关的量 神经毒性或治疗中断四周或更长时间。另外， 无进展存活率和存活率也将被估计。

In this study the primary objective is to assess the feasibility of fixed schedule suramine plus combined androgen suppression (orchiectomy plus flutamide, or LHRH agonist plus flutamide) in a cooperative group setting in patients with newly diagnosed Stage D2 prostate cancer. Feasibility evaluation is based on an assessment of the magnitude of suramine-related neurotoxicity or treatment interruption of four weeks or more. Also, progression-free survival and survival will also be estimated.